SL Science Holding Limited, which began trading on Nasdaq under the ticker SLBT in mid-June 2026 following a SPAC merger, has experienced significant share price swings, drawing attention from investors interested in the biotechnology sector's potential for high rewards and risks.

The company, formerly known as SL BIO Ltd., focuses on developing innovative cellular and gene therapies, with an emphasis on gamma delta T cell platforms targeting solid tumors such as pancreatic and brain cancers. Its Nasdaq listing provides access to U.S. capital markets, potentially accelerating clinical development and strategic partnerships.

Since commencing trading, SLBT shares have shown notable volatility, with prices fluctuating between a 52-week low near $3.00 and highs approaching $14.50. Recent sessions have seen intraday movements exceeding 30% on certain days, reflecting typical patterns for newly public biotech firms with promising but unproven pipelines.

The business combination with Horizon Space Acquisition II Corp. closed with an implied equity valuation of approximately $5.568 billion, accompanied by a $7.8 million PIPE financing. This capital infusion aims to support advancement of the company's proprietary technologies in regenerative medicine and immuno-oncology.

SL Science's core platform involves off-the-shelf gamma delta T cell therapies, which the company believes could........

© International Business Times